Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction

Ineffective erythropoiesis in myelodysplasia is characterized by a defect in erythroid progenitor growth and by abnormal erythroid differentiation. Increased apoptosis of erythroid, granulocytic and megakaryocytic lineages is thought to account for cytopenias. Erythropoietin (Epo)‐induced BFU‐E and CFU‐E growth was studied in 25 myelodysplastic syndrome (MDS) marrow specimens and found to be drastically diminished. To investigate the functionality of Epo‐R in MDS marrow, we focused on Epo‐induced STAT5 activation. Epo was able to stimulate STAT5 DNA binding activity in all normal and 12/24 MDS marrows tested, with no correlation between the level of STAT5 activation and the development of erythroid colonies in response to Epo. In contrast, impaired proliferation of erythroid progenitors was related to an increased expression of the transmembrane mediator of apoptotic cell death Fas/CD95 on the glycophorin A+ subpopulation. Therefore we conclude that the stimulation of pro‐apoptotic signals rather than the defect of anti‐apoptotic pathways resulting from Epo‐stimulated Jak2‐STAT5 pathway, predominantly accounts for ineffective erythropoiesis in myelodysplasia.

[1]  F. Gouilleux,et al.  IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line , 1999, Oncogene.

[2]  R. Kratzke,et al.  Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival , 1999, Leukemia.

[3]  A. Yoshimura,et al.  Proteasomes Regulate Erythropoietin Receptor and Signal Transducer and Activator of Transcription 5 (STAT5) Activation , 1998, The Journal of Biological Chemistry.

[4]  P. Kiener,et al.  A role for tumour necrosis factor‐α, Fas and Fas‐Ligand in marrow failure associated with myelodysplastic syndrome , 1998, British journal of haematology.

[5]  Michael P. Brown,et al.  Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses , 1998, Cell.

[6]  B. Mathey-Prevot,et al.  Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors , 1998 .

[7]  Parker,et al.  Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes , 1998, British journal of haematology.

[8]  M. Jücker,et al.  Carboxyl-Truncated STAT5β Is Generated by a Nucleus-Associated Serine Protease in Early Hematopoietic Progenitors , 1998 .

[9]  J. Price,et al.  Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. , 1998, Blood.

[10]  P. Fenaux,et al.  Fas/APO-1 (CD95) expression in myelodysplastic syndromes. , 1998, Leukemia & lymphoma.

[11]  B. Mathey-Prevot,et al.  Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors. , 1998, Blood.

[12]  K. Hirokawa,et al.  Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes , 1997, Leukemia.

[13]  M. Bondurant,et al.  The roles of Bcl-X(L) and apopain in the control of erythropoiesis by erythropoietin. , 1997, Blood.

[14]  J. D. Vos,et al.  Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes , 1997, Leukemia.

[15]  C. Schindler,et al.  Functionally distinct isoforms of STAT5 are generated by protein processing. , 1997, Immunity.

[16]  S. Burakoff,et al.  Involvement of Proteasomes in Regulating Jak-STAT Pathways upon Interleukin-2 Stimulation* , 1997, The Journal of Biological Chemistry.

[17]  H. Lodish,et al.  Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Yoshimura,et al.  STAT5 Activation Correlates with Erythropoietin Receptor-mediated Erythroid Differentiation of an Erythroleukemia Cell Line* , 1997, The Journal of Biological Chemistry.

[19]  H. Lodish,et al.  Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Hoefsloot,et al.  Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. , 1997, Blood.

[21]  S. Ōmura,et al.  Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway , 1997, Molecular and cellular biology.

[22]  F. Verdier,et al.  Erythropoietin‐induced erythroid differentiation of the human erythroleukemia cell line TF‐1 correlates with impaired STAT5 activation. , 1996, The EMBO journal.

[23]  E. Vellenga,et al.  The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36- sorted bone marrow cells of myelodysplasia patients. , 1996, Blood.

[24]  U. Nir,et al.  Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. , 1996, Leukemia research.

[25]  B. Groner,et al.  Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. , 1996, The EMBO journal.

[26]  L. Hoefsloot,et al.  Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. , 1996, Leukemia.

[27]  P. Greenberg,et al.  Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. , 1996, Blood.

[28]  D Grillot,et al.  Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. , 1996, Blood.

[29]  H. Mori,et al.  Stepwise Movement of Preproteins in the Process of Translocation across the Cytoplasmic Membrane of Escherichia coli(*) , 1995, The Journal of Biological Chemistry.

[30]  S. Ōmura,et al.  Degradation Process of Ligand-stimulated Platelet-derived Growth Factor β -Receptor Involves Ubiquitin-Proteasome Proteolytic Pathway * , 1995, The Journal of Biological Chemistry.

[31]  J. Krosl,et al.  Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin‐induced cell proliferation and Stat5 activation. , 1995, The EMBO journal.

[32]  Rudolf Jaenisch,et al.  Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.

[33]  H. Preisler,et al.  Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. , 1995, Blood.

[34]  N. Young,et al.  Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. , 1995, Blood.

[35]  O. Silvennoinen,et al.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin , 1993, Cell.

[36]  B. Löwenberg,et al.  Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome. , 1992, Blood.

[37]  N. Casadevall,et al.  Erythropoietin induces the tyrosine phosphorylation of its own receptor in human erythropoietin-responsive cells. , 1992, The Journal of biological chemistry.

[38]  M. Koury,et al.  Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. , 1990, Science.